Characterization of Cannabinoids in Cannabidiol (CBD) Products by Lopez, McCayla
   CHARACTERIZATION OF CANNABINOIDS  
   IN CANNABIDIOL (CBD) PRODUCTS 
 
 
   By 
   MCCAYLA LOPEZ 
   Bachelor of Science in Biology  
   University of North Texas 
   Denton, Texas 
   2017 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   MASTER OF SCIENCE 
   May, 2019  
ii 
 
   CHARACTERIZATION OF CANNABINOIDS  
   IN CANNABIDIOL (CBD) PRODUCTS 
 
 
   Thesis  Approved: 
 
   Dr. Jarrad Wagner 
 Thesis Adviser 
   Dr. Russell Lewis 
 
   Dr. Mark Payton 
iii 
Acknowledgements reflect the views of the author and are not endorsed by committee 





I would like to thank everyone who helped me throughout my graduate program. Thank 
you to Dr. Wagner for helping me become a better student. Without your help, I would not be 
where I am today. To Dr. Lewis and Dr. Payton, my committee members, thank you for helping 
advise me and making my research the best it can be. I would also like to thank the faculty and 
staff of the Forensic Sciences program for all their support and words of encouragement. 
I would also like to thank Austin Ciesielski for being a great friend and mentor during my 
years at OSU. I would also like to thank Paige Fisk and Gina Fader for their support and 
friendship during my time in Tulsa.  
To my family, mom and dad without your support and words of encouragement I would 
not have made it this far. I know you did not always understand what I was talking about, but you 
helped me learn how to explain things better. To my sister, Taylor, thank you for all the miles you 
have traveled between Tulsa and Stillwater when you knew I needed a familiar face. To my 
friend Anna Lackey, thank you for all the support you have shown and all the free editing you 
have provided me over the years. I would also like to thank my grandparents for helping me 
throughout my life, I am a better person because you have made me who I am. 
iv 
 
Name: MCCAYLA LOPEZ   
 
Date of Degree: MAY, 2019 
  
Title of Study: CHARACTERIZATION OF CANNABINOIDS IN CANNABIDIOL 
PRODUCTS 
 
Major Field: FORENSIC SCIENCES 
 
Abstract: The purpose of this research was to determine what cannabinoids other than 
cannabidiol (CBD) can be found in various CBD products, as well as determine their 
legality. CBD is federally a Schedule I drug, although CBD products are legal for sale in 
the State of Oklahoma if they contain less than 0.3% tetrahydrocannabinol (THC). Many 
CBD products sold do not have all the cannabinoids in the product included on the label, 
which could be a health risk. The samples in this study were purchased from CBD shops 
in Oklahoma and provided to Oklahoma State University (OSU) for analysis. Liquid 
chromatography with ultra-violet detection and liquid chromatography with mass 
spectrometry were used to separate 12 different cannabinoids commonly found in the 
Cannabis plant. The results showed that all five products had a higher amount of CBD 
than any other cannabinoid. It was also found that when CBD was present, 
cannabidivarin (CBDV) was also present, although most packages did not indicate the 
presence of cannabinoids other than CBD. All products contained at least two 
cannabinoids, with the highest concentration being CBD. All products tested were 
determined to have false information on their packaging, although they are legal in the 
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Cannabidiol (CBD) has become a well-known alternative to pain relief over the past few 
years, not only in the United States, but world-wide. It is classified as a cannabinoid, which 
comes from the Cannabis plant, mainly known as marijuana. It has been found to counteract the 
effects of tetrahydrocannabinol (THC), which is the main psychoactive component in Cannabis. 
(Zuardi et al. 2006) CBD was originally legalized in Oklahoma for children with epilepsy. In 
2017, it became legal for any adult over the age of 18 to buy CBD products.  
While THC has been extensively researched, little is known about the exact mechanism 
of CBD and other cannabinoids, including their drug-drug interactions. Because CBD products 
have not been used for long, there is not much data on what cannabinoids can be found in them. 
This has caused a gap in research that needs to be conducted for public health, as well as forensic 
purposes. Many states are experiencing issues with marijuana prosecutions because CBD and 
hemp is legalized, and the main defense to these prosecutions is CBD or hemp products. 
 Most studies testing CBD products only determined the concentrations of THC, CBD, 
and their acidic forms. This study will look for 12 different cannabinoids. These cannabinoids 
were determined by looking at guidelines for labs testing these products in states with legalized 
Cannabis. Both liquid chromatography with ultra-violet detection and liquid chromatography 
tandem mass spectrometry were used for confirmation. Both methods are utilized to determine 






REVIEW OF LITERATURE 
 
2.1 Introduction 
Marijuana is frequently used across the world. Although illegal in many countries, it has 
begun to be legalized in many areas due to the possible medicinal properties of some of the 
compounds found in Cannabis. In the United States, every state has a different stance, while the 
federal government has stayed the same. Marijuana is still classified federally as a Schedule I 
drug, meaning it has a high potential for abuse, no accepted medical use, and lacks accepted 
safety for use. This research is being conducted because some states have only legalized high 
cannabidiol (CBD) and low tetrahydrocannabinol (THC) products. These products are currently 
unregulated. 
2.2 Laws Related to CBD 
 California was the first state to legalize the medical use of marijuana in 1996. (Mead 
2017) As of June 2018, 31 states, the District of Columbia, Guam, and Puerto Rico have 
implemented these laws. (NCSL 2018) An additional 15 states allow high CBD, low THC 
products to be sold for medicinal use. (NCSL 2018) Only 4 states do not allow the use of any 
products made from Cannabis. The federal government still views any product that comes from 
Cannabis as illegal. In 1970 the Controlled Substances Act was formed. All drugs were placed
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in one of five schedules depending on their abuse potential, accepted medical use in the US, and 
its safety and potential for addiction. (Anderson 2018) Cannabis, and its components, were 
placed in Schedule I. There have been many petitions to move CBD further down the list because 
there has been research to show it possesses some medicinal properties.  
 In May 2014, legislation was passed by the House of Representatives to stop the Drug 
Enforcement Administration (DEA) from targeting legal medicinal marijuana operations. (Fasinu 
et al. 2016) Under the Obama Administration, the U.S. Department of Justice issued a 
memorandum stating it would not prosecute medical marijuana patients and caregivers in states 
where it is legal. (Gostin et al. 2018) However, in January 2018, Attorney General Jeff Sessions 
issued a memorandum rescinding the previous guidance. (Gostin et al. 2018) The goal of the new 
guidance is to prevent minors’ access to marijuana. This guidance has caused major controversy 
with many prosecutors stating they will continue to use the guidelines provided by the Obama 
Administration. (Gostin et al. 2018) 
 In April 2015, Oklahoma Governor Mary Fallin signed HB 2154. This bill, also known as 
Katie’s Law, helped children with epilepsy obtain high CBD, low THC oils and products to help 
with treatment. (procon.org 2018) In 2016, the bill was amended to include adults. It also added 
other conditions to the list, including spasticity due to multiple sclerosis or paraplegia, intractable 
nausea and vomiting, and appetite stimulation with chronic wasting diseases, as long as they have 
written certification from a doctor. In 2017, the bill was amended again, there could be no more 
than 0.3% THC in the products, and almost anyone could obtain them. (Echols and Yen 2017) 
 In August 2018, medicinal marijuana became legal in Oklahoma. Title 310, Chapter 681 
sets the rules for medicinal marijuana. Its definition of marijuana states, “all parts of a plant of the 
genus cannabis, whether growing or not; the seeds…the resin…and every compound, 
manufacture, salt, derivative, mixture or preparation…” (Bailey 2018) Medicinal marijuana 
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products have a slightly different definition, “a product that contains cannabinoids that have been 
extracted from plant material or resin…and is intended for administration to a qualified 
patient…” (Bailey 2018) Standards have been created for medicinal marijuana by 12 Oklahoma 
residents that have unique qualifications related to food safety and are experts in the marijuana 
industry. (Bailey 2018) 
2.3 Compounds found in Cannabis 
 More than 500 compounds have been identified in cannabis. (Lafaye et al. 2017) They 
fall into three main groups: cannabinoids, terpenes, and phenolic compounds. Cannabinoids are 
the major group of compounds found and have been the most researched with about 104 
identified. (Lafaye et al. 2017) Cannabinoid concentration varies with the species of Cannabis, as 
well as with the part of the plant used and the time of the harvest. The endocannabinoid system 
was discovered in 1990. It has two receptors, CB1 and CB2. CB1 receptors are found mainly in the 
brain, while CB2 receptors are found in immune and hematopoietic cells. (Fasinu et al. 2016) CB1 
receptors are found at the terminals of the neurons. They affect cognition, memory, motor 
movements, and pain perception. (Atakan 2012) CB2 receptors will increase in the nervous 
system in response to peripheral nerve damage. (Hill et al. 2017) 
2.3.1 Cannabinoids 
There is a lot of debate about the health benefits of cannabis and its compounds. The 
main benefit of marijuana is in the treatment of chronic pain. (Hill et al. 2017) There have been 
many studies indicating cannabis can produce acute pain-inhibitory effects, but more research 
needs to be done to understand the effects of using cannabis for pain. There have also been some 
reports about the decrease of opioid dependence and overdoses in states with medical marijuana. 
(Hill et al. 2017) THC exhibits anti-inflammatory, anti-cancer, analgesic, muscle relaxants, 
neuro-antioxidative, and anti-spasmodic activities. (Andre et al. 2016) Δ9-THC is the major 
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psychoactive component of cannabis and is the most studied of the compounds. Δ8-THC does not 
significantly contribute to any activity of the plant and is the isomerization of Δ9-THC. (Izzo et al. 
2009) Δ9-THC is a partial agonist of CB1 and inhibits neurotransmitter release. (Atakan 2012) 
Cannabinol (CBN) was the first cannabinoid isolated and was originally thought of as the 
active component. (Izzo et al. 2009) It is a product of Δ9-THC oxidation, so as Δ9-THC degrades, 
CBN increases. It has a lower affinity for CB1 and a higher affinity for CB2 compared to THC, 
affecting the immune system more than the nervous system. (Andre et al. 2016) 
Cannabichromene (CBC) is one of the major cannabinoids found in fresh cannabis. (Izzo et al. 
2009) CBC exhibits some anti-inflammatory, sedative, analgesic, antibacterial and antifungal 
properties. (Andre et al. 2016) Another major cannabinoid is cannabigerol (CBG). It also exhibits 
antibacterial and anti-proliferative activity. (Izzo et al. 2009) Both CBC and CBG have low 
affinity for both CB receptors. (Izzo et al. 2009)  
Tetrahydrocannabivarin (THCV) and cannabicarin (CBDV) are found at higher 
concentrations in Cannabis indica, where CBDV is the precursor to THCV. (Rock et al. 2013). In 
vivo work has shown CBDV’s potential in anti-inflammatory effects and its effectiveness as an 
anti-convulsant in animal models. It acts as an agonist at human transient receptor potential 
(TRP) channels. (Rock et al. 2013) THCV acts as a receptor antagonist for CB1 and CB2 
receptors, and it activates the CB2 receptors. It can reduce food intake and body weight, reduce 
seizures in animal models, reduce inflammation and inflammatory pain, and can reduce 
Parkinson’ s disease symptoms. (Rock et al. 2013) 
Cannabinoids are accumulated as cannabinoid acids in the plant. As the plant is dried, 
stored, or heated they decarboxylize into their neutral forms. Δ9-tetrahydrocannabinolic acid 
(THCA) exerts anti-proliferative and anti-spasmodic actions. (Izzo et al. 2009) Cannabidiol acid 
(CBDA) also exerts anti-proliferative actions. CBDA is 95% of CBD in fresh plant material. 
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(Izzo et al. 2009) In some cases, there are still concentrations of the acids. When smoking occurs, 
they become the decarboxylated forms, and are not seen at high concentrations. (Fasinu et al. 
2016) 
There are many health risks associated with marijuana use: cardiovascular effects, 
respiratory problems, endocrine effects, birth defects, and cognitive function. Acute marijuana 
use can cause an increase in heart rate and blood pressure. (Khalsa 2007) Higher doses can cause 
increased cardiac output. (Khalsa 2007) Bronchitis, coughing, and wheezing are associated with 
chronic heavy marijuana smoking. In marijuana-only smokers, impairment of pulmonary 
function, pulmonary responsiveness, and bronchial cell characteristics are found. (Khalsa 2007) 
Smoking marijuana could also lead to histopathological changes that precede lung cancer and 
increase the risk of respiratory cancer. (Khalsa 2007) Many studies indicate marijuana affects 
endocrine and reproductive functions, from hormone secretion to the birth of children. (Khalsa 
2007) Chronic, high doses of THC can lower testosterone secretion, impair semen and sperm, and 
disrupt the ovulatory cycle. (Khalsa 2007) There is some evidence that suggests prenatal exposure 
of marijuana can lead to postnatal developmental deficits. (Khalsa 2007) 
There is also evidence to suggest that chronic use is associated with “…impairment of 
cognition, particularly affecting short-term memory and executive functioning in humans…”. 
(Khalsa 2007) Patients that were abstinent for 28 days or longer recovered their cognitive 
function. (Khalsa 2007) This indicates that marijuana use causes only short-term memory 
function, and not long-term function. Daily marijuana smokers demonstrated withdrawal 
symptoms, proving that marijuana does produce dependence. (Khalsa 2007) 
2.3.2 Terpenes 
Terpenes are the largest group of compounds found in cannabis and are responsible for 
the odor and flavor of cannabis strains. (Andre et al. 2016) They are classified into families by 
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their number of repeating units of 5-carbon building blocks. (Andre et al. 2016) Terpenes vary 
similarly to cannabinoids based on the part of the plant harvested and the species. There is a 
positive correlation between the amounts of terpenes and cannabinoids found in the plant. 
Terpenes are lipophilic and easily cross membranes. There are many terpenes that are also found 
in different plants. They have an array of health benefits similar to those found in cannabinoids. 
(Andre et al. 2016) 
2.3.3 Phenolic Compounds 
Phenolic compounds make up the last group identified in cannabis. They are one of the 
most widely distributed groups in plants. (Andre et al. 2016) About 20 flavonoids, a type of 
phenolic compound, in cannabis have been identified. They also exhibit many of the health 
benefits found in both cannabinoids and terpenes, and have mainly presented anti-inflammatory, 
anti-cancer, and neuroprotective properties. (Andre et al. 2016) 
2.3.4 Synthetic Cannabinoids 
In recent years, a number of synthetic cannabinoids have been created. Only a few have 
been approved by the Food and Drug Administration (FDA). Dronabinol is a synthetic THC 
approved for treating anorexia in patients suffering from AIDS. It can also be used to treat nausea 
and vomiting in patients undergoing chemotherapy. (Lafaye et al. 2017) Nabilone is another 
synthetic THC also used to help with chemotherapy nausea and vomiting. (Porter 2017) 
Nabixomols is a combination of synthetic THC and CBD equally used to treat spastic pain in 
patients with neurological disorders. It has not been approved by the FDA but has approval in 
several other countries. (Lafaye et al. 2017) In June 2018, the FDA approved the first drug with 
an active ingredient from cannabis. Epidiolex is an oral solution with CBD to treat seizures 





 CBD is thought to counteract the effects of THC and could be up to 40% of the extract in 
cannabis. (Zuardi et al. 2006) Over the past few years, the ratio of THC:CBD has changed. THC 
has increased while CBD decreased. From 1995 to 2014, the potency of 38,681 seized samples of 
marijuana were tested. There was an 8% increase in THC and a 0.5% decrease in CBD. (Lafaye 
et al. 2017) This increase in the ratio could lead to higher risks of psychotic effects. (Lafaye et al. 
2017) 
 Because CBD’s effects are different than THC’s, it might have some significant health 
benefits. The main medicinal purpose is to help control seizures in people with epilepsy. 
However, there is not enough proof to definitively state CBD has antiepileptic activity. (Lafaye et 
al. 2017) There are many uses for CBD products as it has been shown to display some anxiolytic 
effects, as well as antipsychotic and anti-inflammatory affects. Grotenhermen, et al., found that 
high doses of CBD alone do not produce THC like effects, meaning CBD is not psychoactive. 
(Grotenhermen et al. 2017) This is one of the many reasons it has become marketable and been 
given legal status in many states. Many people turn to these products even though they are not 
under the guidance of good manufacturing practices and do not have regulations placed on them. 
(Iffland and Grotenhermen 2017) 
 CBD is a pleiotropic drug, meaning it produces multiple effects in different pathways. 
This can lead to a multitude of potential uses. As an antipsychotic, it has been associated with 
fewer adverse effects than typical antipsychotics. (Izzo et al. 2009) CBD has also been shown to 
produce anxiolytic actions, possibly due to its activity with serotonin receptors. (Izzo et al. 2009) 
CBD is also an antioxidant and can exert neuroprotective actions that could be used to treat 
neurodegenerative diseases. (Izzo et al. 2009) 
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CBD can be delivered in many different forms, similarly to THC. When taken orally, it 
has a small bioavailability, about 6%. It is highly affected by the first pass effect. (Fasinu et al. 
2016) CBD is highly lipophilic, so it accumulates quickly into adipose tissues and is highly 
bound to proteins and blood cells. (Fasinu et al. 2016) Smoking, as with most xenobiotics, has the 
highest bioavailability at around 31%. It is mainly excreted in feces, and a small amount is 
excreted in urine. CBD has a half-life of 18-32 hours. (Fasinu et al. 2016) 
There are not many studies on drug-drug interactions with CBD. There have been a few 
studies on the effects CBD has with cytochrome P450-enzymes. CBD is partially metabolized by 
CYP3A4, which metabolizes about 60% of clinically prescribed drugs. (Iffland and 
Grotenhermen 2017) Some studies have shown that CBD can inactivate CYP450 isozymes for a 
short time but will induce them after continued administration in mice. (Iffland and 
Grotenhermen 2017) It is also a potent inhibitor of CYP2C, CYP2D6, an CYP3A isoforms. 
(Fasinu et al. 2016) 
2.5 Cannabis Products 
Cannabinoids can be provided in many different products. The most common and pure 
samples are tinctures, which are oils that can be placed under the tongue. (Ministry of Hemp 
2016) Concentrates usually have the strongest dosage and are consumed the same as tinctures. 
(Ministry of Hemp 2016) The most popular type of concentrate is shatter. (Ministry of Hemp 
2016) Topicals have also become popular. Similar to lotion, the topical is rubbed into the skin to 
theoretically help treat chronic pain, inflammation, acne, psoriasis, and anti-aging. (Ministry of 
Hemp 2016) Vapes are also popular because these oils can be placed in a vape pen and can be 
consumed at the user’s leisure. (Ministry of Hemp 2016) Edibles have also become very popular, 
especially in places with legalized marijuana. In 2014, 4.81 million units of Cannabis edibles 
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were purchased in Colorado. (Wiley et al. 2016) Edibles can be anything from gummy candies to 
brownies and cookies.  
There have been many challenges associated with Cannabis products. In states where 
edibles are legal, there has been an increase in emergency room visits of children because the 
packaging can be appealing. (Wiley et al. 2016) Another issue is these products are unregulated, 
meaning there is a lack of standardization in the formulation of the products, so two formulations 
of the same edible made by the same company could have very different potencies from each 
other. (Wiley et al. 2016) Even when there is mandated threshold testing, variations could still 
occur. This means that most labels are inaccurate.  
From 2015-2017, the FDA has tested many products claiming to contain CBD. Many of 
the products tested did not contain the levels of CBD that the package claimed. (FDA 2017) A 
study conducted by Bonn-Miller et al., analyzed 84 CBD products from 31 companies sold online 
to determine the accuracy of labeling. (Bonn-Miller et al. 2017) Thirty-six of the products were 
under-labeled, 22, were over-labeled, and 26 were labeled accurately. (Bonn-Miller et al. 2017) 
The concentration of unlabeled cannabinoids in these products was low, with THC detectable in 
18 of the samples. (Bonn-Miller et al. 2017) Vandrey el al., also conducted a labeling study for 
products containing cannabinoids. (Vandrey et al. 2015) They purchased 75 products in three of 
the biggest cannabinoid industries: San Francisco, Los Angeles, and Seattle. They found that 17% 
were labeled correctly, 23% were under-labeled, and 60% were over-labeled. (Vandrey et al. 
2015) These results show that the labels on cannabinoid product packaging is not always reliable, 
and it does not always represent everything in these products. 
2.6 Previous Analyses  
 When a substance thought to be marijuana is brought into a lab for analysis, the first step 
is usually the Duquenois-Levine test. This test has been used for over 80 years in forensic labs. 
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(Jacobs and Steiner 2014) It consists of three parts and will react with THC to produce a purple 
color. (Jacobs and Steiner 2014) The Duquenois reagent can cross react with many different 
substances, leading to many false positives. When the Levine reagent is added, it eliminates the 
potential of false positives due to the addition of chloroform. Molecules with long aliphatic 
chains can cross the chloroform layer, which includes THC. (Jacobs and Steiner 2014) Another 
preliminary test for marijuana is observation under a microscope. Cystolithic hairs are good 
indicators of plant material because no other plants have these hairs. (NCSCL 2016) According to 
SWGDRUG, there should be at least two tests performed to determine the identity of the 
substance. (SWGDRUG 2016) 
 However, it is difficult to run a preliminary test on a cannabis product. Since they come 
in many different forms, it can be complicated to determine if there is anything in these products. 
A few methods have been implemented in forensic drug labs, but they are not perfect. The most 
common confirmatory test in these labs is gas chromatography with either a mass spectrometer or 
flame-ionization detector. Both of these tests could be problematic if the scientist is unsure what 
they are looking for.  
 Terpenes are chemically unstable in many extraction techniques. Like the cannabinoid 
acids, they are thermally liable. (Omar et al. 2013) Omar et al. focused on finding an extraction 
method that would assure they could be seen. Supercritical fluid extraction (SFE) can be used 
because it requires low temperature and pressure during extractions. They were able to see both 
cannabinoids and terpenes in different extractions using different extraction parameters. (Omar et 
al. 2013) They proved that terpenes could be seen in GC-MS despite the high temperatures used. 
Fischedick et al., also found a way to view terpenes using GC-FID. (Fischedick et al. 2010) 
However, neither study looked at cannabis products, but at various species of Cannabis sativa.  
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Pellegrini et al. created a GC/MS procedure to determine cannabinoids in hemp food 
products. (Pellegrini et al. 2005) They tested three products found in Italy: liqueur, pastilles, and 
seeds. They found using the European Union standard of 0.2% THC that none of the products 
were considered illegal. (Pellegrini et al. 2005) They also found that the concentrations of CBD 
and CBN were lower than THC in all products tested. (Pellegrini et al. 2005) None of the studies 
conducted using GC in combination with FID or MS could identify the cannabinoid acids because 
they are thermally unstable and decarboxylize to their neutral forms under high heat. Therefore, 
liquid chromatography with either an ultraviolet or diode-array detector or an MS detector would 
be better to find the acids. LC does not need to super heat samples like GC does.  
Brighenti et al., determined dynamic maceration was the best extraction method for 
identifying cannabinoids in hemp using both LC-UV and LC-MS/MS. (Brighenti et al. 2017) 
Their results show CBDA as the most abundant compound, followed by CBD, which was 4-10 
times lower than CBDA. (Brighenti et al. 2017) Peace et al., evaluated two CBD formulations 
used in electronic cigarettes. Both formulations were from the same manufacturer and claimed to 
be produced with a hemp strain with the highest CBD potency allowed. (Peace et al. 2016) Both 
contained at least twice the amount of CBD than what the manufacturer claimed, and the only 
cannabinoid found was CBD. (Peace et al. 2016) This could be potentially harmful to those using 
these products because they could be ingesting more than is needed. 
More research needs to be conducted to determine not only what is in CBD products, but 
also at what concentrations these compounds are found. It is dangerous for consumers to 
conclude that the concentration stated on a product is correct because the literature so far shows 
the majority are wrong. It is also dangerous for consumers to use these products when there is 
little data to show what compounds are found in them. This research will help consumers be more 









 Cannabinoids are one of the largest groups of compounds found in Cannabis sativa L. 
plants. THC, the main psychoactive substance in cannabis is classified as a cannabinoid. Some 
people claim cannabis has medicinal purposes; however, because it is illicit, cannabidiol, or CBD, 
is used instead. Many products have been created with CBD in them and these products are legal 
across many states. Some of these products state CBD and THC potencies, but not what else 
might be in them. This project is to develop a method to characterize some of the most common 
cannabinoids in these products.   
3.2 Materials 
 Methanol (Fisher Scientific, Hampton, NH) was HPLC grade. 98% formic acid (EDM 
Millipore Corp, Billerica, MA) was ACS grade. Cannabichromene, cannabidiol, cannabidicarin, 
cannabigerol acid, cannabinolic acid, tetrahyrocannabinolic acid, tetrahydrocannabivarin, and 
androstenedione were ordered from Cerilliant (Cerilliant Corporation, Round Rock, TX). 
Cannabidolic acid, cannabigerol, cannabinol, ∆9-tetrahydrocannabinol, and ∆8-
tetrahydrocannabinol were ordered from Cayman Chemical (Cayman Chemical, Ann Arbor, MI). 
Error! Reference source not found. below shows the standard concentrations and solvents.
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Table 1. Standard concentrations and solvents. 
Standard Concentration Solvent 
Cannabichromene (CBC) 1.0 mg/mL 1 mL Methanol 
Cannabidiol (CBD) 1.0 mg/mL 1 mL Methanol 
Cannabidolic Acid (CBDA) 1.0 mg/mL 1 mL Methanol 
Cannabidivarin (CBDV) 1.0 mg/mL 1 mL Methanol 
Cannabigerol (CBG) 1.0 mg/mL 1 mL Methanol 
Cannabigerol Acid (CBGA) 1.0 mg/mL 1 mL Acetonitrile 
Cannabinol (CBN) 1.0 mg/mL 1 mL Methanol 
Cannabinolic Acid (CBNA) 1.0 mg/mL 1 mL Methanol 
D8-Tetrahydrocannbinol (THC) 1.0 mg/mL 1 mL Methanol 
D9-Tetrahydrocannabinol (THC) 1.0 mg/mL 1 mL Methanol 
Tetrahydrocannabinolic Acid (THCA-A) 1.0 mg/mL 1 mL Methanol 
Tetrahydrocannabivarin (THCV) 1.0 mg/mL 1 mL Methanol 
Androstenedione 1.0 mg/mL 1 mL Acetonitrile 
 
3.3 Instrumentation 
All samples were analyzed with a Shimadzu HPLC system (Shimadzu Corporation, 
Kyoto, Japan) consisting of a system controller, CBM-20A, a solvent delivery unit, LC-20AD, an 
auto-sampler, SIL-20AC, a column over, CTO-20AC, and a UV-vis detector, SPD-20AV. An 
Agilent Poroshell 120, EC-C18, 3.0 x 50 mm, 2.7 µm column was used for LC separation 
(Agilent Technologies, Santa Clara, CA). 
The Shimadzu HPLC system was attached to an Applied Biosystems 4000 Q-Trap LC-
MS/MS System (Applied Biosystems, Foster City, CA). The mass spectrometer was equipped 
with a Turbo V™ electrospray ionization source, a Harvard Apparatus syringe pump (Holliston, 
MA) and a Genius 3020 nitrogen generator as the source of gases for the instrument (Peak 
Scientific Instruments Ltd, Paisley, United Kingdom). Analyst® 1.6.2 Software was used to 






3.4.1 Standard Preparation 
A curve was prepared by adding 100 µL of all 12 cannabinoid standards to methanol to 
create 2 mL of the highest point on the curve, at 50 µg/mL. Curve concentrations of 25 µg/mL, 10 
µg/mL, 5 µg/mL, and 1 µg/mL were created using serial dilution. Three quality controls were 
used at levels of 25 µg/mL, 5 µg/mL, and 0.5 µg/mL. All standards were kept in a freezer 
between -15° and -20° C. The internal standard solution was prepared at 10 µg/mL by adding 50 
µL of androstenedione to methanol to create 5 mL of solution.  
3.4.2 Sample Preparation 
  Solid samples were extracted by weighing 100 mg of dry product. Liquid samples were 
extracted by removing 100 µL. The samples were placed in a clean, labeled microcentrifuge tube, 
100 µL of internal standard solution and 900 µL of methanol was added. The tubes were vortexed 
for 10 seconds, then placed on a shaker at 2000 RPM for 10 minutes. The tubes are then 
centrifuged for 6 minutes at 13000 RPM. Supernatant was removed at a volume of 900 µL and 
placed in a clean tube. Nitrogen was applied to the supernatant until dryness was complete or 
until only the oil remained. The samples were resuspended in 200 µL of running buffer, 40% 
mobile phase A/60% mobile phase B, vortexed, and centrifuged for 6 minutes at 13000 RPM. 
The buffer was removed and placed in vials for analysis.  
3.4.3 Analytical Procedure 
 All unknowns were extracted in triplicate. Each run included a set of calibrators from 
high to low, a set of quality controls high to low, a blank, the unknowns, a blank, the quality 
controls high to low, and the calibrators from low to high. There are two methods used to 
determine the potency, as well as, the cannabinoids present.  
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3.4.4 Liquid Chromatography Parameters 
 The analytes were separated using an Agilent Poroshell 120 EC-C18, 3.0 x 50 mm, 2.7 
µm column. Mobile phase A is 0.1% formic acid in water. Mobile phase B is 0.05% formic acid 
in methanol. A flow rate of 1 mL/min was used for a run time of 11 minutes. The column 
temperature is 50° C. The injection volume is 5 µL. The mobile phase gradient begins at 60% 
mobile phase B, increases to 77% from 1 minute to 6 minutes, increases to 85% from 6 minutes 
to 7.75 minutes, and then increases to 95% from 7.75 minutes to 8.75 minutes. It holds at 95% 
mobile phase B until the end of the run at 9.5 minutes. An equilibration time of 1.5 minutes was 
utilized to return to starting conditions. 
3.4.5 Ultra Violet Detection Parameters 
 Both the tungsten and deuterium lamps were used. The wavelength detector was set to 
230 nm and ran for 9.5 minutes. 
3.4.6 Mass Spectrometry Parameters 
 The mass spectrometer is used to identify the cannabinoids by their masses. The MS was 
run in both positive and negative mode. Positive mode is used to identify androstenedione. 
Negative mode is used to identify the 12 cannabinoids. Error! Reference source not found. 
shows the optimized parameters for each analyte.   
Table 2. Mass Spectrometer Parameters for each analyte. 
Polarity Q1 Mass Q3 Mass Retention Time Analyte DP CE CXP 
Negative 313.081 190.996 8.24 CBC -70 -30 -9 
Negative 313.081 178.916 8.24 CBC 2 -70 -26 -13 
Negative 313.092 244.997 6.32 CBD -100 -32 -13 
Negative 313.092 178.967 6.32 CBD 2  -100 -28 -9 
Negative 356.785 244.952 6.61 CBDA -60 -40 -15 
Negative 356.785 178.967 6.61 CBDA 2 -60 -28 -9 
Negative 285.068 217.026 4.75 CBDV -65 -32 -11 
Negative 285.068 150.937 4.75 CBDV 2 -65 -26 -9 
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Polarity Q1 Mass Q3 Mass Retention Time Analyte DP CE CXP 
Negative 315.062 191.987 6.39 CBG -100 -30 -11 
Negative 315.062 136.032 6.39 CBG 2 -100 -38 -7 
Negative 359.018 315.193 7.07 CBGA -50 -38 -9 
Negative 359.018 148.984 7.07 CBGA 2 -50 -22 -13 
Negative 309.037 279.057 7.28 CBN -105 -44 -15 
Negative 309.037 221.889 7.28 CBN 2 -105 -60 -13 
Negative 353.931 310.077 8.45 CBNA -5 -32 -17 
Negative 353.931 279.926 8.45 CBNA 2 -5 -50 -15 
Negative 313.096 244.993 7.83 D8-THC -70 -40 -5 
Negative 313.096 191.052 7.83 D8-THC 2 -70 -40 -13 
Negative 313.046 244.949 7.69 D9-THC -95 -40 -3 
Negative 313.046 191.112 7.69 D9-THC 2 -95 -40 -17 
Negative 357.308 313.064 8.79 THCA-A -110 -50 -15 
Negative 357.308 245.005 8.79 THCA-A 2 -110 -44 -13 
Negative 285.107 216.937 6.18 THCV -80 -34 -7 
Negative 285.107 162.959 6.18 THCV 2  -80 -40 -9 
Positive 287.14 109.056 1.7 Androstenedione 71 27 6 
Positive 287.14 97.105 1.7 Androstenedione 2 71 31 2 
 
3.4.7 Percentage Determination 
 Because most packaging shows the percentage of cannabinoids in the products, 
determining their percentage was necessary. The equation: %CB = [CB] x (DIL) x (VOL/MG) x 
100	is used. [CB] is the concentration of the cannabinoid in µg/mL. (DIL) is the dilution factor 
used. VOL is the external volume of methanol added to the vial. MG is the sample weight used in 









4.1 LC/UV Results 
 Concentrations and percentages of the cannabinoids were determined using the UV 
method described above. The Ultra-Premium Hemp Oil Tincture (Gold Tincture), Gold Spectrum 
Full Spectrum Hemp Oil (Gold FSHO), and Bee’s Knee’s CBD’s (Bee’s Knees) were oils. The 
SAT-A-VET Chewable CBD for pets (SAT-A-VET) was a soft pet treat. The Blue Dream Kalm 
Concentrate (Kalm Concentrate) was a shatter. All five products were purchased at a CBD store 
in Oklahoma City. Error! Reference source not found. displays the concentrations. The 
products had high levels of CBD and CBG, as well as low levels of CBDV. Four of the products 
had some detectable level of THC. The percentages of CBD ranged from 0.1% to 2.7%. Error! 
Reference source not found. shows the percentages of each cannabinoid in all five products. 
Peaks representing the cannabinoids were determined by relative retention time. The relative 
retention time was determined by subtracting the retention time of the analyte and the retention 
time of the internal standard. The peak was determined positive if it was within plus or minus 








Gold Tincture SAT-A-VET Kalm Concentrate 
Gold 
FSHO Bee's Knees 
CBC  N/D N/D 2.6 N/D 1.5 
CBD 357.0 145.3 5215.0 1343.3 135.0 
CBDA 4.2 N/D N/D 109.2 N/D 
CBDV 8.1 4.0 24.6 93.8 5.7 
CBG 23.3 13.6 328.5 23.2 7.9 
CBGA 2.0 N/D 4.1 N/D 6.9 
CBN N/D N/D 2.2 2.7 N/D 
CBNA N/D N/D N/D N/D 3.1 
∆8-THC N/D N/D N/D 2.4 1.8 
∆9-THC 3.1 N/D 3.2 N/D 4.1 
THCA N/D N/D 1.2 N/D N/D 
THCV 8.3 6.1 3.8 N/D N/D 
N/D denotes the cannabinoid was not detected in this sample. 
Table 4. Percentages of cannabinoids found in LC/UV analysis. 
Cannabinoids 
Percentages Gold Tincture SAT-A-VET Kalm Concentrate Gold FSHO Bee's Knees 
CBC  N/D N/D 0.0% N/D N/D 
CBD 0.2% 0.1% 2.7% 0.7% 0.1% 
CBDA 0.0% N/D N/D 0.1% N/D 
CBDV 0.0% 0.0% 0.0% 0.0% 0.0% 
CBG 0.0% 0.0% 0.2% 0.0% 0.0% 
CBGA 0.0% N/D 0.0% N/D N/D 
CBN N/D N/D 0.0% 0.0% N/D 
CBNA N/D N/D N/D N/D 0.0% 
∆8-THC N/D N/D N/D 0.0% 0.0% 
∆9-THC 0.0% N/D 0.0% N/D 0.0% 
THCA N/D N/D 0.0% N/D N/D 
THCV 0.0% 0.0% 0.0% N/D N/D 
N/D denotes the cannabinoid was not detected in this sample. 
 Example chromatograms of the LC/UV methods are shown in Figure 1, Figure 6, Figure 
3, Figure 4, Figure 5, and Figure 6. Figure 1 displays an example chromatogram of the highest 
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calibrator at 50 µg/mL. Figures 2 through 6 display examples of the unknown samples 
chromatograms. 
 
Figure 1. Sample chromatogram of the LC/UV 50 µg/mL calibrator. 
 
 

















Figure 3. Sample chromatogram of the LC/UV SAT-A-VET extract. 
 
 




Figure 5. Sample chromatogram of the LC/UV Gold FSHO extract. 
 
 







4.1.1 LC/UV Statistical Analysis  
GraphPad Prism® version 7.04 was used for statistical analysis. CBDV, CBD, and CBG 
were found in all five products. They were compared using ANOVA. The Kalm Concentrate was 
not used in the ANOVA because it was an outlier. The values determined for CBDV, CBD, and 
CBG were determined to be outliers using Grubbs’ Test and therefore was not was not used in the 
ANOVA post-test. THCV, CBGA, and ∆9-THC were found in three of the five products and 
were also compared using ANOVA. THCV, CBGA, and ∆9-THC include the Kalm Concentrate 
although it only has two replicates. Table 5 shows the comparisons. In the table below, there exist 
significant differences among the means as tested with ANOVA. Within a response variable, two 
means with the same letter are not significantly different using a Fisher-type pairwise comparison 
at a 0.05 level. The cannabinoid was not detected in the product if N/D is denoted. 
Table 5. Means and standard deviations of cannabinoids in each product using LC/UV with 
ANOVA post-test denotations. 
 Cannabinoids Gold Tincture SAT-A-VET Gold FSHO Bee's Knees Kalm Concentrate 
CBDV 8.1b±0.5 4.0c±0.0 19.3a±2.1 10.0b±0.9   
CBD 357.0b±39.0 145.3c±5.7 1343.3a±105.0 135.0b±36.3   
CBG 23.3a±7.9 13.6b±0.1 23.2a±6.3 7.9c±4.7   
CBGA 2.0c±0.0 N/D N/D 6.9a±0.9 4.1b±0.2 
Δ9-THC 3.1a±0.2 N/D N/D 4.1a±0.9 3.2a±0.4 
THCV 8.3a±0.5 6.1b±0.3 N/D N/D 3.8c±0.3 
Two means with the same letters are not significantly different from each other at a 0.05 level. 
Comparisons are done across the rows. 
 
4.2 LC-MS/MS Results 
 Concentrations and percentages of the cannabinoids were determined using the MS 
method described above. Table 6 displays the concentrations. All products were positive for CBD 
and CBDV. Two of the products had some detectable level of THC. The percentages of CBD 
ranged from 0% to 1.4%. Table 7 shows the percentages of each cannabinoid in all five products. 
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The Gold FSHO saturated the detector for CBDA, therefore there is not an accurate concentration 
and greater than upper limit of quantitation (> ULQ) is provided for the concentration and 
percentage.  




Gold Tincture SAT-A-VET Kalm Concentrate Gold FSHO Bee's Knees 
CBC  N/D N/D N/D N/D N/D 
CBD 133.0 86.5 2660.0 2450.0 200.7 
CBDA 2.6 N/D 26.3 > ULQ N/D 
CBDV 10.4 2.1 986.0 392.0 39.6 
CBG N/D N/D N/D 138.3 N/D 
CBGA N/D N/D N/D 249.3 N/D 
CBN N/D N/D 11.6 29.7 2.1 
CBNA N/D N/D N/D 2.2 N/D 
∆8-THC N/D N/D N/D N/D N/D 
∆9-THC N/D N/D N/D N/D 11.8 
THCA N/D N/D N/D 16.0 N/D 
THCV N/D N/D N/D N/D 19.3 
N/D denotes the cannabinoid was not detected in this sample. 
Table 7. Percentages of cannabinoids found in LC-MS/MS analysis. 
Cannabinoids 
Percentages Gold Tincture 
SAT-A-
VET Kalm Concentrate Gold FSHO Bee's Knees 
CBC  N/D N/D N/D N/D N/D 
CBD 0.1% 0.0% 1.4% 1.2% 0.1% 
CBDA 0.0% N/D 0.0% > ULQ N/D 
CBDV 0.0% 0.0% 0.5% 0.2% 0.0% 
CBG N/D N/D N/D 0.1% N/D 
CBGA N/D N/D N/D 0.1% N/D 
CBN N/D N/D 0.0% 0.0% 0.0% 
CBNA N/D N/D N/D 0.0% N/D 
∆8-THC N/D N/D N/D N/D N/D 
∆9-THC N/D N/D N/D N/D 0.0% 
THCA N/D N/D N/D 0.0% N/D 
THCV N/D N/D N/D N/D 0.0% 
N/D denotes the cannabinoid was not detected in this sample. 
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 Example chromatograms of the LC-MS/MS method are shown in Figure 7, Figure 8, 
Figure 9, Figure 10, Figure 11, Figure 12, and Figure 13. Figure 7 displays an example 
chromatogram of the highest calibrator at 50 µg/mL. Figure 8 shows the same chromatogram 
with the ion transitions for CBG and CBGA extracted. CBG and CBGA had the same retention 
times, therefore they were not seen as individual peaks in the total ion chromatogram. Figures 8 
through 13 are representative chromatograms for the unknown samples used in the study. Some 
of the peaks are not shown in the total ion chromatogram because the peaks for CBD have a 
larger height. CBDA saturated the detector in all three extractions of the Gold FSHO.  
 


























Figure 10. Sample chromatogram of the LC-MS/MS SAT-A-VET extract. 
 
 




Figure 12. Sample chromatogram of the LC-MS/MS Gold FSHO extract. 
 
 






4.2.1 LC-MS/MS Statistical Analysis 
 CBD and CBDV was found in all five products using the MS analysis. These 
cannabinoids were compared using the same ANOVA test as above. The Kalm Concentrate was 
not used in the ANOVA because it was an outlier. The values determined for CBD and CBDV 
were determined to be outliers using Grubbs’ Test and therefore were not was not used in the 
ANOVA post-test. CBN and CBDA was positive in three of the products tested. CBDA does not 
have an ANOVA test because Gold FSHO was saturated. CBN does include Kalm Concentrate. 
show the results. In the table below, there exist significant differences among the means as tested 
with ANOVA. Within a response variable, two means with the same letter are not significantly 
different using a Fisher-type pairwise comparison at a 0.05 level. The cannabinoid was not 
detected in the product if N/D is denoted. 
Table 8. Means and standard deviations of cannabinoids in each product using LC-MS/MS with 
ANOVA post-test denotations. 
Cannabinoid Gold Tincture SAT-A-VET Gold FSHO Bee's Knees Kalm Concentrate 
CBD 133.0b±1.0 86.5b±3.7 2450.0a±182.5 200.7b±38.1   
CBDV 10.4c±1.1 2.1c±0.1 392.0a±15.6 39.6b±8.8   
CBN N/D N/D 29.7a±7.8 2.1b±1.5 11.6b±0.5 
Two means with the same letters are not significantly different from each other at a 0.05 level. 
Comparisons are done across the rows. 
 
4.3 Method and Packages Comparison 
 An issue with CBD products is misinformation on the packaging. The five samples used 
in this study ranged from having no information about the amount of CBD to having the amount 
of CBD per serving. For comparison purposes, the concentrations obtained for each sample were 
calculated to equal 1 mL. Table 9, Table 10, Table 11, Table 12, and Table 13 Table 9. Gold 
Tincture Comparison.show the concentrations and percentages of each cannabinoid found in each 
product. The asterisk designates that the concentrations of the cannabinoids was statistically 
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different between the two analyses according to an unpaired t-test using a confidence interval of 
0.05. If the cannabinoid was not detected during the analysis, N/D was used in place of a number.  
Table 9. Gold Tincture Comparison. 











CBD 3570* 1.8% 1330* 0.7% 2000 1% 
CBDA 41.6* 0.0% 26.1* 0.0% N/D N/D 
CBDV 80.8* 0.0% 103.7* 0.1% N/D N/D 
CBG 233.3 0.1% N/D N/D 10 0.50% 
CBGA 19.7 0.0% N/D N/D N/D N/D 
∆9-THC 31.3 0.0% N/D N/D N/D N/D 
THCV 83.4 0.0% N/D N/D N/D N/D 
*designates the concentrations are statistically different between the two methods 
Table 10. SAT-A-VET Comparison. 











CBD 1453.3* 0.7% 865* 0.4% 6000 3% 
CBDV 39.8* 0.0% 21.4* 0.0% N/D N/D 
CBG 136 0.1% N/D N/D N/D N/D 
THCV 60.8 0.0% N/D N/D N/D N/D 
*designates the concentrations are statistically different between the two methods 
Table 11. Kalm Concentrate Comparison. 











CBC 26.1 0.0% N/D N/D N/D N/D 
CBD 52150 27.4% 26600 14.1% 180000 90% 
CBDA N/D N/D 262.5 0.1% N/D N/D 
CBDV 246* 0.1% 9860* 5.2% N/D N/D 
CBG 3285 1.7% N/D N/D 4000 2% 
CBGA 40.5 0.0% N/D N/D N/D N/D 
CBN 21.8* 0.0% 115.5* 0.1% N/D N/D 
∆9-THC 31.6 0.0% N/D N/D N/D N/D 
THCA 12.4 0.0% N/D N/D N/D N/D 
THCV 37.9 0.0% N/D N/D N/D N/D 
*designates the concentrations are statistically different between the two methods 
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Table 12. Gold FSHO Comparison. 











CBD 13433.3* 6.7% 24500* 12.2% 60000 30% 
CBDA 1091.7 0.5% >ULD N/D N/D N/D 
CBDV 938* 4.7% 3920* 2.0% N/D N/D 
CBG 232* 0.1% 1383.3* 0.7% N/D N/D 
CBGA N/D N/D 2493.3 1.2% N/D N/D 
CBN 26.5* 0.0% 297.3* 0.2% N/D N/D 
CBNA N/D N/D 22.1 0.0% N/D N/D 
∆8-THC 24.5 0.0% N/D N/D N/D N/D 
THCA N/D N/D 159.7 0.1% N/D N/D 
*designates the concentrations are statistically different between the two methods 
Table 13. Bee’s Knees Comparison 











CBC 14.6 0.0% N/D N/D N/D N/D 
CBD 1350 0.6% 2006.7 1.0% N/D N/D 
CBDV 57.5* 0.0% 396* 0.2% N/D N/D 
CBG 79.4 0.0% N/D N/D N/D N/D 
CBGA 68.5 0.0% N/D N/D N/D N/D 
CBN N/D N/D 21.1 0.0% N/D N/D 
CBNA 30.7 0.0% N/D N/D N/D N/D 
∆8-THC 17.5 0.0% N/D N/D N/D N/D 
∆9-THC 40.7* 0.0% 117.7* 0.1% N/D N/D 
THCV N/D N/D 193 0.1% N/D N/D 










5.1 Product Comparison 
5.1.1 LC/UV Comparison 
 All five products had detectable amounts of CBD, CBG, and CBDV. Four of the products 
had a detectable amount of THC or THCA. All products had at least four cannabinoids, with the 
Kalm Concentrate and Bee’s Knees having the most cannabinoids at eight each. The highest 
concentration of the standards was 50 µg/mL. Any concentration above that number is an 
estimation because it is above the quantitation level. Other cannabinoids were detected in each 
product below the lower limit of 1 µg/mL and were therefore not included in the study. 
 The Gold Tincture and Bee’s Knees were not significantly different when comparing 
CBDV concentrations. The Kalm Concentrate had the highest overall concentration but could not 
be used due to its insufficient number of replicates. The concentration of CBD was higher than all 
the other cannabinoids, which was expected. SAT-A-VET and Bee’s Knees were not significantly 
different when comparing CBD. They had the lowest concentrations. Gold FSHO was only 
significantly different from Bee’s Knees when comparing CBG. Most of the concentrations found 
were around 20 µg/mL, except the Kalm Concentrate.  
 THCV was found in three of the products. Gold Tincture, SAT-A-VET, and Kalm 
Concentrate were all significantly different from each other. CBGA was also found in three 
products, Gold Tincture, Kalm Concentrate, and Bee’s Knees. They were also significantly 
different from each other. ∆9-THC was found in Gold Tincture, Bee’s Knees, and Kalm
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Concentrate, and were not significantly different from each other. 
CBDA was found at a low concentration in the Gold Tincture and at a high concentration 
in Gold FSHO. CBN was also found at low concentrations in Kalm Concentrate and Gold FSHO. 
∆8-THC was found in Gold FSHO and Bee’s Knees. CBC was found in Kalm Concentrate and 
Bee’s Knees. Only Bee’s Knees contained CBNA and THCA was only found in Kalm 
Concentrate. 
 Overall, the Kalm Concentrate had the highest concentrations of cannabinoids present. 
Since concentrates are known for having the highest potency on the market, this makes sense. 
The SAT-A-VET pet treats had the lowest concentration of cannabinoids present.  
5.1.2 LC-MS/MS Comparison 
  All five products had detectable amounts of CBD and CBDV. Two of the products had a 
detectable amount of THC or THCA. All products had at least two cannabinoids, with Gold 
FSHO having the most cannabinoids at eight. The highest concentration of the standards was 50 
µg/mL. Any concentration above that number is an estimation because it is above the quantitation 
level. Other cannabinoids were detected in each product below the lower limit of 1 µg/mL and 
were therefore not included in the study. One product, Gold FSHO, saturated the MS detector. 
Therefore, there is not a concentration provided for CBDA for this product.  
 Only Gold FSHO was significantly different from all other products when comparing 
CBD. The other products were not significantly different from each other. Gold Tincture and 
SAT-A-VET were not significantly different from each other when comparing CBDV. All other 
products were significantly different. CBN and CBDA were positive in three of the products. Due 
to the saturation of Gold FSHO, CBDA was not compared statistically. For CBN, Bee’s Knees 
and Gold FSHO were significantly different, as were Gold FSHO and Kalm Concentrate.  
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 Only Gold FSHO contained CBG, CBGA, CBNA, and THCA. Bee’s Knees was the only 
product that contained ∆9-THC and THCV. However, in the last replicate run, THCV was not 
detected. CBC and ∆8-THC were not found in any of the products. 
5.1.3 Comparison of Methods 
 The results obtained between the two analyses were different. A main reason for this 
could be the specificity obtained with the LC-MS/MS method versus the LC/UV method. The 
LC-MS/MS looks for specific mass transitions, while the LC/UV looks for an absorbance that is 
common to cannabinoids but not necessarily specific. Both methods utilized chromatography, and 
it was found that the relative retention times varied by about 7.5% across all the calibrators, 
quality controls, and unknown samples. This is slightly more variation than is usually acceptable 
in a liquid chromatography method, and it is apparent that the wider variation depended on the 
specimen type. For instance, it was observed early in method development that oil-based products 
caused a shift to the left in the chromatogram (eluting earlier), and therefore the approach of 
extraction into solvents, followed by dry down and resuspension in running buffer, was utilized. 
It is felt that future work should attempt to measure actual extraction efficiencies from each 
product type, and somehow normalize results to account for the variations in extraction 
efficiency. It was more difficult to discern peaks on the LC/UV than the LC-MS/MS, as there 
were far more peaks in a given retention time window via LC/UV than LC/MS/MS.  The analyst 
determined if the cannabinoid was present by verifying the peak was within 7.5% of expected.  
 The methods agreed that CBD and CBDV were found in all products. However, CBG 
was found in all products using the LC/UV but was only found in Gold FSHO using the 
LC/MSMS. There were also less positives for THC in the LC/MSMS than were found in the 
LC/UV. With the exception of Gold FSHO and Bee’s Knees, the total concentrations and 
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percentages of cannabinoids in the products was higher with the LC/UV. Most of the products 
had a higher number of cannabinoids identified in the LC/UV method.   
5.2 Actual v. Expected Percentages  
 It is important to point out that the products themselves presented a variety of matrices 
that created challenges in complete and consistent cannabinoid extraction. While internal standard 
was used to control for extraction efficiency somewhat, the studies did not discern between 
potential matrix effects and actual differences in extraction efficiencies. 
The Gold Tincture had a serving size of 1 mL on the packaging. In the 1 mL serving, 
there should be 10 mg, or 1%, CBD and 0.5 mg, or 0.05%, CBG. The percent of CBD determined 
for 1 mL in the LC/UV method was 1.8% and 0.7% in the LC-MS/MS method. For CBG, 0.1% 
was detected in the LC/UV method and there was no detectable amount in the LC-MS/MS 
method. The total cannabinoid percent found in the LC/UV method was 2% and, in the LC-
MS/MS method, was 0.7%. The SAT-A-VET treats claimed 1.5 mg of the 50 mg treat, or 3%, 
was CBD and an additional 5 mg, or 10%, was hemp extract. The percent determined per treat 
was 0.7% CBD and 0.8% total cannabinoids in the LC/UV method. In the LC-MS/MS method, 
0.4% CBD and 0.4% total cannabinoids.  
The Gold FSHO packaging stated 30% Active CBD and no other cannabinoids were 
represented on the packaging. Since this was not given as a serving, it was assumed that this 
number was for the total volume of 1 mL. The percent determined for 1 mL was 6.7% in the 
LC/UV method. The total percent of cannabinoids present is 7.9%. The LC-MS/MS method 
determined 12.2% CBD and 16.3% overall cannabinoids. The Kalm Concentrate stated 90% 
CBD and 2% CBG. Because there is no serving size provided on the packaging, 1 mL was 
assumed. The actual percent calculated for 1 mL was 27.4% CBD and 1.7% CBG. The total 
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cannabinoids present was 29% in the LC/UV method. The total percent of cannabinoids found in 
the LC-MS/MS method was 19.6%, with 14.1% CBD and no CBG found.  
The Bee’s Knees packaging contained no information about serving size or the 
cannabinoids present in the product. There were three syringes with 50 mg each in the packaging. 
Since there are three syringes, it was assumed one syringe is one serving. There was 0.3% CBD 
in each serving, with total cannabinoids determined as 0.4% in the LC/UV method. The LC-
MS/MS method found 0.5% CBD and 0.6% total cannabinoids. 
All five products have incorrect labeling. Three of the five products had concentrations 
lower than stated on the package using both the LC/UV and the LC-MS/MS for comparison. Gold 
Tincture was higher when using the LC/UV method for comparison, but lower when using the 
LC-MS/MS method for comparison. The fifth, Bee’s Knees, had no information about 
concentrations of cannabinoids. All products had more cannabinoids than were stated on the 
labels.  
5.3 Conclusions 
 The results found in this study were consistent with results found in other studies. All 
CBD products tested were determined to be legal because they had low detectable amounts of 
THC. None of the packaging on the products tested were correct, due to a lack of regulations in 
Oklahoma. Most CBD products are created using Cannabis indica. This seems to be true of the 
products used in this study. Cannabis indica has a lower concentration of THC, and has higher 
concentrations of the other, non-psychoactive cannabinoids.  
The LC-MS/MS method may be more reliable than the LC/UV method because mass 
spectrometry is more sensitive and more reliable with retention time identification. While the 
LC/UV method did work, there was more noise and because you cannot create a retention time 
window, it was harder to identify for certain which peaks were cannabinoids due to the peak 
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shifting in the samples. The noise is most likely due to the many other compounds that are present 
in these products. Terpenes are common in CBD products because they help with flavor and odor. 
Artificial flavors may have also been added to help with the taste. There are also many more 
cannabinoids than those looked for in this research. This can also lead to an increase in peaks in 
the LC/UV chromatogram. 
There are many issues with products containing phytocannabinoids. Most have inaccurate 
data on their labels and do not provide serving sizes. This is a challenge to novel consumers, as 
well as experienced users, which can lead to adverse reactions. Regulations are needed to solve 
this problem. Another issue with these products is the lack of research on the non-psychoactive 
cannabinoids. While they do not cause the “high” associated with products containing THC, most 
of their mechanisms of action are not known. There is also a lack of drug-drug interaction studies, 
which could cause major problems for many people. The current study points to the presence of a 
multitude of cannabinoids, and shows the need for future research to characterize CBD products 
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